| Literature DB >> 29165360 |
Dario Gioia1, Martina Bertazzo2,3, Maurizio Recanatini4, Matteo Masetti5, Andrea Cavalli6,7.
Abstract
Molecular docking is the methodology of choice for studying in silico protein-ligand binding and for prioritizing compounds to discover new lead candidates. Traditional docking simulations suffer from major limitations, mostly related to the static or semi-flexible treatment of ligands and targets. They also neglect solvation and entropic effects, which strongly limits their predictive power. During the last decade, methods based on full atomistic molecular dynamics (MD) have emerged as a valid alternative for simulating macromolecular complexes. In principle, compared to traditional docking, MD allows the full exploration of drug-target recognition and binding from both the mechanistic and energetic points of view (dynamic docking). Binding and unbinding kinetic constants can also be determined. While dynamic docking is still too computationally expensive to be routinely used in fast-paced drug discovery programs, the advent of faster computing architectures and advanced simulation methodologies are changing this scenario. It is feasible that dynamic docking will replace static docking approaches in the near future, leading to a major paradigm shift in in silico drug discovery. Against this background, we review the key achievements that have paved the way for this progress.Entities:
Keywords: binding kinetics; drug discovery; enhanced sampling; molecular dynamics; protein-ligand binding
Mesh:
Substances:
Year: 2017 PMID: 29165360 PMCID: PMC6150405 DOI: 10.3390/molecules22112029
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Examples of some of the most popular currently available docking software. For a comprehensive list see [15].
| Software | Searching Algorithm | Native Scoring Function 1 | License |
|---|---|---|---|
| AutoDock [ | Stochastic | Force-Field based | Free for Academia |
| DOCK [ | Systematic | Force-Field based | Free for Academia |
| FlexX [ | Systematic | Empirical | Paid |
| Glide [ | Systematic | Empirical | Paid |
| GOLD [ | Stochastic | Force-Field based | Paid |
| ICM [ | Stochastic | Force-Field based | Paid |
| MOE [ | Stochastic | Force-Field based | Paid |
1 Usually, the user can choose among several, often customizable, scoring functions. Here we report the type of scoring functions originally developed with the docking program.
Figure 1Sequential combination of docking and MD simulations. (a) MD employed for rescoring or refining docking poses; (b) MD employed for conformational ensemble generation. Docking is then performed against multiple rigid receptor conformations.
Figure 2Schematic representation of hot-spots identified through solvent mapping approaches. The displayed co-solvent mixture is taken from [54].
Figure 3In metadynamics the bias is applied to a CV (q) in order to fill the underlying free energy (F(q)) and discouraging the system to visit already sampled states.
Figure 4REMD does not rely on a priori definition of CVs. Several replicas of the system at different temperature (T) are simulated independently with the possibility to exchange coordinates at regular intervals.
Comparative time scales of brute force MD versus discontinuous approaches as reported in retrospective studies. Owing to the inherent difficulties in comparing timescales of several short trajectories, adaptive sampling is not considered in this table.
| Author (Year) | Complex | Multiple Ligands | No. of Runs | Aggregate Time | Productive Runs 1 | Time to Binding |
|---|---|---|---|---|---|---|
| Shan et al. (2011) | PP1/Src kinase | y | 7 | 115 µs | 3 | 15.1–1.9–0.6 µs |
| Dasatinib/Src kinase | y | 4 | 35 µs | 1 | 2.3 µs | |
| Buch et al. (2011) | Benzamidine/Trypsine | n | 495 | 49.5 µs | 187 | 15–90 ns |
| Dror et al. (2011) | Dihydroalprenolol/ | y | 40 | 111.8 µs | 5 | NA |
| Alprenolol/ | y | 10 | 14 µs | 1 | NA | |
| Propranolol/ | y | 21 | 35.7 µs | 0 | - | |
| Isoprotenerol/ | y | 1 | 15.0 µs | 0 | - | |
| Dihydroalprenolol/ | y | 10 | 55.5 µs | 2 | NA | |
| Kruse et al. (2012) | ACh/M3 R | y | 1 | 25 µs | 1 | 9.5 µs |
| Tiotropium/M3 R | y | 3 | 18 µs | 0 | - | |
| Tiotropium/M2 R | y | 3 | 16.2 µs | 0 | - | |
| Decherchi et al. (2015) | DADMe-immucilin-H/PNP | y | 14 | 7 µs | 3 | 340 ns |
| Sabbadin et al. (2014) | ZM241385/hA2A | n | 3 | - | 1 | 59 ns |
| T4G/hA2A | n | 3 | - | 1 | 62 ns | |
| T4E/hA2A | n | 3 | - | 1 | 105 ns | |
| Caffeine/hA2A | n | 3 | - | 1 | 15.2 ns | |
| Cuzzolin et al. (2016) | Ellagic Acid/CK2 | n | 3 | - | 0 | - |
| SAPS/GSTP1-1 | n | 3 | - | 2 | 27–19 ns | |
| Benzen-1,2-diol/PRDX5 | n | 3 | - | 3 | 17.4–31.2–18 ns | |
| ( | n | 3 | - | 0 | - | |
| ( | n | 3 | - | 0 | - | |
| NECA/hA2A | n | 3 | - | 0 | - | |
| Zeller et al. (2017) | Oseltamivir/neuraminidase | n | 676 | 50.0 µs | ~20 | NA |
| Zanamivir/neuraminidase | n | 606 | 35.7 µs | ~20 | NA | |
1 “Productive” refers to simulations that reproduced the crystallographic pose within a given RMSD threshold.
Figure 5Schematic representation of unbiased MD approaches to dynamic docking. The most populated state should, in principle, correspond to the energetic minimum.
Examples of MD software that can be used to perform dynamic docking simulation.
| Software | GPU Support | Biased MD Support | PLUMED 2.3 Patch Available | License |
|---|---|---|---|---|
| MD Engines | ||||
| ACEMD [ | x | x | x 1 | Free Serial Version (for Academia) |
| AMBER [ | x | x | x | Paid |
| CHARMM [ | x | x | Free Serial Version | |
| Desmond [ | x | x | Free for Academia | |
| DL_POLY [ | x | x | x 1 | Free for Academia |
| GROMACS [ | x | x | x | Free |
| LAMMPS [ | x | x | x | Free |
| NAMD [ | x | x | x | Free |
| ORAC [ | x | Free | ||
| Tinker [ | x | Free | ||
| Software Interfaces | ||||
| BiKi Life Sciences | - | - | - | Paid |
| HTMD | - | - | - | Free Basic Version (for Academia) |
| SEEKR | - | - | - | Free |
1 PLUMED is natively supported by the MD engine.